Silo Pharma Inc., a developmental stage biopharmaceutical company, has announced the pricing of a $2 million public offering. The offering includes 3,333,338 shares of common stock along with Series A-1 and Series A-2 warrants, each allowing the purchase of an additional 3,333,338 shares at $0.60 per share. The Series A-1 Warrants will expire five years from issuance, and the Series A-2 Warrants will expire eighteen months from issuance. H.C. Wainwright & Co. is serving as the exclusive placement agent for this offering. The company plans to use the proceeds for general working capital purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.